137 related articles for article (PubMed ID: 11472461)
1. An economic evaluation of atenolol vs. captopril in patients with Type 2 diabetes (UKPDS 54).
Gray A; Clarke P; Raikou M; Adler A; Stevens R; Neil A; Cull C; Stratton I; Holman R;
Diabet Med; 2001 Jun; 18(6):438-44. PubMed ID: 11472461
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):720-6. PubMed ID: 9732339
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):713-20. PubMed ID: 9732338
[TBL] [Abstract][Full Text] [Related]
4. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.
UK Prospective Diabetes Study Group
BMJ; 1998 Sep; 317(7160):703-13. PubMed ID: 9732337
[TBL] [Abstract][Full Text] [Related]
5. Hypertension in Diabetes Study IV. Therapeutic requirements to maintain tight blood pressure control.
Diabetologia; 1996 Dec; 39(12):1554-61. PubMed ID: 8960842
[TBL] [Abstract][Full Text] [Related]
6. An economic evaluation of atenolol vs. captopril in patients with type 2 diabetes (UKPDS 24).
Caro JJ; Lee K
Curr Hypertens Rep; 2002 Dec; 4(6):417. PubMed ID: 12419165
[No Abstract] [Full Text] [Related]
7. Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Matthews DR; Stratton IM; Aldington SJ; Holman RR; Kohner EM;
Arch Ophthalmol; 2004 Nov; 122(11):1631-40. PubMed ID: 15534123
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72).
Clarke PM; Gray AM; Briggs A; Stevens RJ; Matthews DR; Holman RR;
Diabetologia; 2005 May; 48(5):868-77. PubMed ID: 15834550
[TBL] [Abstract][Full Text] [Related]
10. Hypertension in Diabetes Study. III. Prospective study of therapy of hypertension in type 2 diabetic patients: efficacy of ACE inhibition and beta-blockade.
Diabet Med; 1994 Oct; 11(8):773-82. PubMed ID: 7851072
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypertensive and hypercholesterolaemic patients in general practice. The effect of captopril, atenolol and pravastatin combined with life style intervention.
Foss OP; Graff-Iversen S; Istad H; Søyland E; Tjeldflaat L; Graving B
Scand J Prim Health Care; 1999 Jun; 17(2):122-7. PubMed ID: 10439497
[TBL] [Abstract][Full Text] [Related]
12. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
CDC Diabetes Cost-effectiveness Group
JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
[TBL] [Abstract][Full Text] [Related]
14. A predictive model of the health benefits and cost effectiveness of celiprolol and atenolol in primary prevention of cardiovascular disease in hypertensive patients.
Milne RJ; Vander Hoorn S; Jackson RT
Pharmacoeconomics; 1997 Sep; 12(3):384-408. PubMed ID: 10170463
[TBL] [Abstract][Full Text] [Related]
15. The effects of replacing beta-blockers with an angiotensin converting enzyme inhibitor on the quality of life of hypertensive patients.
Paran E; Anson O; Neumann L
Am J Hypertens; 1996 Dec; 9(12 Pt 1):1206-13. PubMed ID: 8972892
[TBL] [Abstract][Full Text] [Related]
16. Antihypertensive therapy in type 2 diabetes mellitus.
Miser WF
J Fam Pract; 1998 Dec; 47(6):413-4. PubMed ID: 9866657
[No Abstract] [Full Text] [Related]
17. Antihypertensive therapy with verapamil SR plus trandolapril versus atenolol plus chlorthalidone on glycemic control.
Holzgreve H; Nakov R; Beck K; Janka HU
Am J Hypertens; 2003 May; 16(5 Pt 1):381-6. PubMed ID: 12745200
[TBL] [Abstract][Full Text] [Related]
18. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Pharmacoeconomics; 2009; 27(3):221-30. PubMed ID: 19354342
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes.
Pahor M; Psaty BM; Alderman MH; Applegate WB; Williamson JD; Furberg CD
Diabetes Care; 2000 Jul; 23(7):888-92. PubMed ID: 10895836
[TBL] [Abstract][Full Text] [Related]
20. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK.
Tilden DP; Mariz S; O'Bryan-Tear G; Bottomley J; Diamantopoulos A
Pharmacoeconomics; 2007; 25(1):39-54. PubMed ID: 17192117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
